Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Updates in Pediatric Atopic Dermatitis : Episode 11

Opinion

Video

March 10, 2025

New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors

Author(s):

Lisa Swanson, MD, FAAD,Lawrence Eichenfield, MD

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

EP: 1.Updates in Pediatric Atopic Dermatitis

EP: 2.Pathophysiology and Role of Type 2 Inflammation in Pediatric Atopic Dermatitis

EP: 3.Talking to Patients and Families About Type 2 Inflammatory Conditions

EP: 4.Unpacking the Atopic Dermatitis Burden of Disease With Patients and Families

EP: 5.Unique Challenges in Managing Atopic Dermatitis in Pediatric Patients

EP: 6.New Nonsteroid Topical Treatments for Pediatric Atopic Dermatitis: Topical Ruxolitinib

EP: 7.New Nonsteroid Topical Treatments for Pediatric Atopic Dermatitis: Topical Roflumilast

EP: 8.New Nonsteroid Topical Treatments for Pediatric Atopic Dermatitis: Topical Tapinarof

EP: 9.New Systemic Therapies for Pediatric Atopic Dermatitis: Dupilumab and IL-13 Inhibitors

EP: 10.Understanding and Treating Pediatric AD Inside and Out

Now Viewing

EP: 11.New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors

EP: 12.Future Directions for Pediatric Atopic Dermatitis Management and Research

Video content above is prompted by the following:

Moving on to systemic treatment options, let’s discuss some of the newer systemic treatment options available for pediatric AD, including mechanism of action, efficacy, and safety: